TY  - RPRT
TI  - Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
AU  - Ko, M.
AU  - Jeon, S.
AU  - Ryu, W.-S.
AU  - Kim, S.
PY  - 2020
DO  - 10.1101/2020.05.12.090035
UR  - https://www.biorxiv.org/content/10.1101/2020.05.12.090035v1
ID  - 10.1101/2020.05.12.090035
ER  -